{"schema_version":"secwatch.filing_event.v1","accession":"0001178670-24-000039","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.352331+00:00","generated_at":"2026-05-31T13:40:17.142395+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Alnylam Q2 net product rev $410M +34% YoY; HELIOS-B positive; guidance raised","bullets":["Global net product revenue $410M, up 34% YoY; TTR business (ONPATTRO+AMVUTTRA) grew 37% YoY.","HELIOS-B Phase 3 vutrisiran met primary endpoint (28% reduction composite); all-cause mortality reduced 36% in overall population.","GAAP net loss $16.9M; non-GAAP net income $73.8M ($0.58 non-GAAP diluted EPS).","Raised 2024 combined net product revenue guidance from $1.4-1.5B to $1.575-1.65B.","Planned sNDA submission for vutrisiran using Priority Review Voucher; Phase 3 for ALN-TTRsc04 at year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001178670-24-000039","json":"https://secwatch.observer/filing/0001178670-24-000039.json","markdown":"https://secwatch.observer/filing/0001178670-24-000039.md","text":"https://secwatch.observer/filing/0001178670-24-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000117867024000039/0001178670-24-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000117867024000039/alny-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:40:17.142395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}